MedPath

Combination therapy of interferon-alpha and interleukin-2 for patients with metastatic renal cell carcinoma after failure of targeted therapy because of adverse events

Not Applicable
Recruiting
Conditions
metastatic renal cell carcinoma
Registration Number
JPRN-UMIN000017717
Lead Sponsor
Department of Urology, The University of Tokyo Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1. allergic reaction for biological products such as vaccine 2. autoimmune hepatitis 3. interstitial pneumonitis 4. female during pregnancy or lactation 5. receiving steroid hormone therapy 6. progressive disease during prior targeted therapy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath